การรอดชีพและผลการรักษาของโรคมะเร็งเม็ดเลือดขาวเฉียบพลันชนิดมัยอิลอยด์ในผู้ใหญ่ที่เข้ารับการรักษาด้วยเคมีบำบัดของโรงพยาบาลสวรรค์ประชารักษ์

Klaijith  Wongyai

Authors

Klaijith Wongyai Swanpracharak Hospital

Keywords:

Acute Myeloid Leukemia, Overall Survival, Chemotherapy, Cytogenetic Risk, Regional Hospital

Abstract

Methods: This retrospective descriptive study reviewed medical records of 87 AML patients, aged 18 years and older, who were treated with standard induction chemotherapy between 2018 and 2022. Data were analyzed using percentages, means, and the Kaplan-Meier method for survival analysis.

Results: The mean age of patients was 45.1 years. Most patients (43.7%) were categorized into the intermediate cytogenetic risk group. Following the first induction chemotherapy, 42.5% achieved complete remission (CR). However, a high mortality rate of 73.6% was observed during the initial chemotherapy phase, primarily due to pulmonary fungal infections (29%) and pneumonia (24%). The median overall survival was 153 days (approximately 5 months). The survival rates at 1 and 2 years were 31.2% and 22.4%, respectively. Notably, the favorable-risk group demonstrated the highest 1-year survival rate at 72.7%, which was statistically significant compared to other risk groups (p-value < 0.01).

Conclusions: AML treatment in a regional hospital setting faces significant challenges due to high induction mortality from infectious complications. However, patients in the favorable cytogenetic risk group showed significantly better outcomes and survival. Enhancing supportive care and infection control measures is crucial to improving survival rates for AML patients in this setting.

Keywords: Acute Myeloid Leukemia, Overall Survival, Chemotherapy, Cytogenetic Risk, Regional Hospital

References

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.

Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003;2003(1):82-101.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70-87.

Niparuck P, Chuncharunee S, Kongtim P, Rojnuckarin P, Bunworasate U, jootar S. Long-term outcomes of de novo acute myeloid leukemia in Thai patients. J Med Assoc Thai. 2009;92(9):1143-9.

Aoki T, Harada Y, Matsumura I. Epidemiology and clinical characteristics of acute myeloid leukemia in Asian countries. Int J Hematol. 2020;112(3):312-22.

Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36(7):1703-19.

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354-65.

Mrózek K, Heinonen K, de la Chapelle A, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol. 1997;24(1):17-31.

Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(5):503-13.

Shallis RM, Lorenz R, Gillis N, Bewersdorf JP, Podoltsev NA, Ma X, et al. Acute myeloid leukemia in the older adult: A review of biology, treatment, and outcomes. Cancer Treat Rev. 2021;99:102264.

Sawant M, El-Rikabi O, Sathyamoorthy M, et al. Therapeutic challenges and survival trends in acute myeloid leukemia: An analysis of population-based registry datasets. Blood Rev. 2024;42(2):101-15.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103(4):620-5.

Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4−week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97(1):68-78.

O'Donnell MR, Abboud CN, Altman J, Altman JK, Appelbaum FR, Arber DA, et al. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(7):926-57.

Short NJ, Konopleva M, Kadia TM, Borthakur G, Ravandi F, DiNardo CD, et al. Advances in the treatment of acute myeloid leukemia: new drugs and new challenges. Cancer Discov. 2020;10(4):506-25.

Estey EH. Acute myeloid leukemia: 2021 maintenance therapy and more. Am J Hematol. 2021;96(3):354-65.

Perl AE. The role of FLT3 inhibitors in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2017;58(5):1035-49.

Medinger M, Passweg JR. Allogeneic stem cell transplantation for acute myeloid leukemia in elderly patients. Semin Hematol. 2016;53(4):254-9.

Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909-18.

Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-4187.

Wanitpongpun C, Utchariyaprasit E, Owattanapanich W, Tantiworawit A, Rattarittamrong E, Niparuck P, et al. Types, clinical features, and survival outcomes of patients with acute myeloid leukemia in Thailand: A 3-year prospective multicenter study from the Thai Acute Leukemia Study Group (TALSG). Clinical Lymphoma Myeloma and Leukemia. 2021;21(9):e635-e643.